個(gè)人簡(jiǎn)歷

社會(huì)任職：

北京藥理學(xué)會(huì)藥物代謝專(zhuān)業(yè)委員會(huì)委員

《現(xiàn)代藥物與臨床》青年編委

《中國(guó)臨床藥理學(xué)雜志》青年編委

個(gè)人簡(jiǎn)介：

1. 教育背景

2002.09 ~ 2007.06 河北醫(yī)科大學(xué)，臨床醫(yī)學(xué)系，醫(yī)學(xué)學(xué)士

2007.09 ~ 2010.06 上海交通大學(xué)，醫(yī)學(xué)免疫學(xué)，醫(yī)學(xué)碩士2012.09 ~ 2015.06 復(fù)旦大學(xué)，藥理學(xué)，理學(xué)博士

2. 工作經(jīng)歷

2010.07 ~ 2017.09 上海市徐匯區(qū)中心醫(yī)院, I期臨床試驗(yàn)研究室

2017.11 ~ 2019.12 首都醫(yī)科大學(xué)宣武醫(yī)院，藥物研究室，藥理學(xué)博士后

2020.01 ~至今 首都醫(yī)科大學(xué)宣武醫(yī)院，藥學(xué)部，I期臨床研究中心

3. 科研水平

主要從事藥物早期臨床試驗(yàn)研究工作，作為助理研究者完成I期臨床試驗(yàn)和生物等效性試驗(yàn)100余項(xiàng)，作為主要研究者5項(xiàng);對(duì)創(chuàng)新藥物的安全耐性研究、藥代動(dòng)力學(xué)和藥效學(xué)研究、食物影響和物料平衡試驗(yàn)、藥物-藥物相互作用研究、以及仿制藥的生物等效性研究，在方案設(shè)計(jì)、試驗(yàn)實(shí)施和質(zhì)量管理方面具有豐富的實(shí)踐經(jīng)驗(yàn)。

作為負(fù)責(zé)人獲批5項(xiàng)課題，其中國(guó)家級(jí)1項(xiàng)、省部級(jí)1項(xiàng)、局級(jí)2項(xiàng)和院級(jí)課題1項(xiàng);入選2020年度北京市醫(yī)院管理中心青苗計(jì)劃;以第一作者和共同第一作者發(fā)表SCI論文12篇，參與發(fā)表核心期刊論文50余篇。

主持課題：

1) 國(guó)家自然科學(xué)基金青年項(xiàng)目，81903880，基于NLRP3炎性小體調(diào)控機(jī)制探討淫羊藿苷調(diào)節(jié)小膠質(zhì)細(xì)胞表型極化抑制多發(fā)性硬化免疫炎癥反應(yīng)的研究，2020/01-2022/12，20萬(wàn)，在研;

2) 中國(guó)博士后基金，2019M650776，AGC調(diào)節(jié)TLR4/9信號(hào)通路抑制IS炎癥反應(yīng)的作用機(jī)制研究, 2019/01-2019/11，8萬(wàn)元，結(jié)題;

3) 北京市博士后科研活動(dòng)經(jīng)費(fèi)，2018-ZZ-105，痘苗病毒致炎兔皮提取物治療缺血性腦卒中的機(jī)制研究，2018/06-2019/11，10.3萬(wàn)元，結(jié)題;

4) 上海市徐匯區(qū)衛(wèi)生局青年項(xiàng)目，SHXH201140，LC-MS/MS法測(cè)定維生素E醋酸酯檢測(cè)平臺(tái)的建立及臨床應(yīng)用研究，2012/01-2014/12，3萬(wàn)，結(jié)題;

5) 上海市徐匯區(qū)中心醫(yī)院科研基金重點(diǎn)項(xiàng)目，2011XHCH07，γδ T細(xì)胞與類(lèi)風(fēng)濕性關(guān)節(jié)炎發(fā)病關(guān)聯(lián)性研究，2011/05-2014/04，5萬(wàn)，結(jié)題;

發(fā)表SCI論文：

1) Hu Chaoying, Ji bingxin, Hu Xiao, et al. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study[J]. Clinical Pharmacology in Drug Development. 2021; 10(3):291-298.

2) Hu Chaoying, Lin Qingtang, Liu Chuan, et al. Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal ?) in glioma patients in China[J]. Cancer Chemother Pharmacol. 2020; 86(6):793-801.

3) Hu Chaoying, Chen xiaoping, Zhao Zirun, et al. A Two-Sequence, Four-Period, Crossover, Replicate Study to Demonstrate Bioequivalence of Warfarin Sodium Tablet in Healthy Chinese Subjects Under Fasting and Fed Conditions[J]. Clinical Pharmacology in Drug Development. 2020; 9(4) 527-536.

4) Wang Chunhua&, Hu Chaoying&, Gao Dan et al. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers [J]. Cancer Chemother Pharmacol. 2019; 83:509–517.

5) Hu Chaoying, Hu Xiao, Wang Chunhua, et al. Bioequivalence and Pharmacokinetics of BisoprololAmlodipine 5 mg/5 mg Combination Tablet versus Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet: an open-label, randomized, two-sequence crossover study in Chinese healthy subjects[J]. Clinical Drug Investigation. 2018; 38(12):1145-1154.

6) Hu Chaoying, Yijun Wang, Rong Song, et al. Single- and Multiple-dose Pharmacokinetics of Lurasidone in Healthy Chinese Subjects [J]. Clinical Drug Investigation. 2017; 37(9):861-871.

7) Hu Chaoying, Debbie Tompson, Mindy Magee, et al. Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial [J]. PLOS ONE, 2015; 10(10): e0139862.

8) Hu Chaoying, Jia Jingying, Kelly Dong, et al. Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial [J]. PLOS ONE, 2015; 10(3): e0121264.

9) Liu Yun&, Hu Chaoying&, Li Gangyi, et al. A Replicate Designed Bioequivalence Study To Compare Two Fixed-Dose Combination Products of Artesunate and Amodiaquine in Healthy Chinese Volunteers [J]. Antimicrob Agents Chemother, 2014; 58(10):6009-6015.

10) Hu Chaoying, Liu Yanmei, Liu Yun, et al. Pharmacokinetics and Tolerability of Tenofovir Disoproxil Fumarate 300 mg Once Daily: An Open-Label, Single- and Multiple-Dose Study in Healthy Chinese Subjects [J]. Clinical Therapeutics, 2013; 35(12):1884-1889.

11) Hu Chaoying&, Qian Liu&, Miao Yi, et al. Antigen-presenting effects of effector memory Vγ9Vδ2 T cells in rheumatoid arthritis [J]. Cell Mol Immunol, 2012; 9(3):245-254.

12) Wang Yuan&, Hu Chaoying&, Dong Ruofan, et al. Platelet-derived growth factor-D promotes ovarian cancer invasion by regulation matrix metalloproteinases 3 and 9 [J]. Asian Pacific Journal of Cancer Prevention, 2011; 12(12):3367-3370.